The discrepancies may be largely dependent on the tumor type or the examined biopsy (post-operative vs. post-treated), or the type of therapy (chemotherapy vs. radiotherapy), or be due to the different classification criteria defining nuclear and cytoplasmic Survivin. This evidence concerns the gene BIRC5 and neoplasm.